Honasa buys 58% of Fluence Pharma at ₹135 crore to enter nutraceuticals
What's the deal? Honasa ConsumerDealroom has a profile for this one. Try Dealroom →, the beauty and personal care company behind Mamaearth, will acquire a 58% majority stake in Fluence PharmaDealroom has a profile for this one. Try Dealroom →, a science-backed nutraceuticals firm, at about ₹135 crore enterprise value. The deal is a secondary purchase, subject to closing adjustments and conditions precedent.
How is it structured? Honasa will buy the remaining 42% through secondary purchase in two tranches over five to seven years after completion. It marks the company's entry into the nutraceuticals space.
What's the endgame? Honasa will house the new business under a dedicated subsidiary, Honasa Health Private LtdDealroom has a profile for this one. Try Dealroom →, to scale a business-to-consumer nutrition portfolio. Fluence brings a patented Cyclical Nutrition Therapy that Honasa calls a benchmark for clinically validated efficacy.
Why now? India's nutraceuticals market is valued at over ₹16,000 crore and, per Honasa, at an "inflection point," driven by demand for "beauty-from-inside" products and awareness of nutritional gaps.
What they're saying: "While the last decade was shaped by topical actives, we believe the next decade will be defined by the powerful convergence of science-backed skin and hair care, and nutraceuticals," said co-founder and chief executive officer Varun Alagh.
The signal: The acquisition extends Honasa's "House of Brands" strategy beyond topical beauty into ingestible wellness — a bet that the two categories converge. Alagh framed it as building "a more resilient, diversified growth engine."
Read more: eflip.in
Image credit: Generated with Gemini
